RNA interference (RNAi) has been a revolution in biology, powering over 20 years of scientific pursuit at Alnylam. We believe that laboratory breakthroughs can be transformed into life-changing medicines for patients. We embrace our commitment to responsibly innovate, advance our science and pipeline, invest in R&D, collaborate across sectors, and advocate for science and the biopharmaceutical industry.

Our growth and future success are directly tied to the expertise and passion of our employees. By investing in career development and personal wellbeing, with a focus on inclusion, we promote a culture of belonging where everyone can thrive. We create opportunities for employees to expand their knowledge, advance their proficiency, and incorporate diverse perspectives throughout their work.

Our patients, employees, and business can only thrive when the communities surrounding us are resilient and sustainable. Reducing health inequities, especially removing short- and long-term barriers that limit access to quality health care, stands at the center of our community impact work. Through cross-sector collaboration, innovative investment approaches, and active employee engagement, we seek to improve the underlying social determinants of health that influence health outcomes and enable communities to thrive.

The health of every individual around the world is inextricably linked to the health of our planet. Throughout our business, we seek to minimize our environmental impact, working to address the growing threat of climate change and natural resource depletion. Each year, we focus on measuring, assessing, mitigating, and reporting on our environmental performance.

Strong governance and integrity are cornerstones of our daily operations and planned growth. We adhere to the highest level of ethical, compliance, and legal standards and strive to apply a corporate responsibility lens to business activities.